LONDON, UK: Nestlé announced today that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing. This agreement follows Nestlé’s announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive…